Trending Articles
Latest Publications
-
Building resilient portfolios in 2026 | Wealth DFM 21 | Dec/Jan 2026
Deck the halls with fiscal foresight As we reach the final issue of 2025, I’m delighted to bring you one…
Wealth DFM Talk is our flagship podcast, that fits perfectly into your busy life, bringing the latest insight, analysis, news and interviews to you, wherever you are.
Wealth DFM Talk Podcast – listen to the latest episode
More Latest News
-
Pagaya Announces Pricing of 7,500,000 Class A Ordinary Shares
NEW YORK–(BUSINESS WIRE)–Pagaya Technologies Ltd. (NASDAQ: PGY) (“Pagaya,” the “Company” or “we”), a global technology company delivering artificial intelligence infrastructure for the…
-
BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2023
Focused on delivering cutting edge AI-driven drug discovery LONDON–(BUSINESS WIRE)–Regulatory News: BenevolentAI (“BenevolentAI”, “the Company” or “the Group”) (Euronext Amsterdam: BAI), a…
-
Adenia to Acquire 12 Air Liquide Subsidiaries in Africa
ABIDJAN, Côte d’Ivoire–(BUSINESS WIRE)–#PrivateEquity–Adenia Partners (“Adenia”), a leading private equity firm that has been making responsible and sustainable investments in Africa for…
-
Sensorion Announces the Availability of its Financial Report for 2023
MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies…
-
AFYREN Announces Further Improvement in Its Extra-financial Rating
AFYREN obtained a rating of 83/100 (+4 points vs. 2022) and reaches EthiFinance1 « Platinum » level Concrete achievements in 2023 support…
-
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
MARSEILLE, France–(BUSINESS WIRE)–#ANKET–Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will…
-
Sensorion Reports Full-Year 2023 Financial Results and Business Update
Milestone achieved for SENS-501 gene therapy program with Clinical Trial Application approval in Europe (France as first country) Communication on first patient…
-
Kinetik Announces Pricing of Secondary Offering of Common Stock
HOUSTON & MIDLAND, Texas–(BUSINESS WIRE)–Kinetik Holdings Inc. (NYSE: KNTK) (“Kinetik” or the “Company”) announced today the pricing of an underwritten secondary offering…
-
CORRECTING and REPLACING GrowGeneration Reports Fourth Quarter and Full Year 2023 Financial Results; Provides First Quarter and Full Year 2024 Guidance
Full Year Net Revenue of $225.9 million, Beating Guidance Full Year Net Loss of $46.5 million and Non-GAAP Adjusted EBITDA(1) Loss of…
-
Black & Veatch Studies Extraction of Natural Hydrogen in Australia
Global engineering and construction leader will provide concept designs for H2EX’s natural hydrogen and helium project MELBOURNE, Australia–(BUSINESS WIRE)–Black & Veatch, a…